News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Maarten Beekman, MD

Advertisement

Articles by Maarten Beekman, MD

Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

ByAlexander Bedenkov, MD, PhD,Andrey Ipatov, MD,Filip Surmont, MD,Carmen Moreno,Maarten Beekman, MD,Ryan Bate
October 11th 2019

A look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.

Advertisement

Latest Updated Articles

  • Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations
    Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

    October 11th 2019



Advertisement
Advertisement

Trending on PharmExec

1

Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection

2

FDA Reveals New Guidance for Streamlining Biosimilar Development

3

Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12

4

Pharmaceutical Executive Daily: FDA's New Guidance for Biosimilar Development

5

Cautious Momentum: Biopharma Review and Outlook

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us